Supplemental Table S5. Adjusted ORs for Patients Who Were Confirmed with COVID-19 and Negative Test Controls (Hypertension and Fasting Blood Sugar)

	No. (%)		Total cohort		PS-matched cohort	
	Case	Control	Adjusted OR (95% CI)	*P* value	Adjusted OR (95% CI)	*P* value
Hypertension						
Overall						
Normal	946 (42.4)	32,084 (43.3)				
Elevated	306 (13.7)	10,070 (13.6)	0.968 (0.845–1.107)	0.632	0.980 (0.853–1.127)	0.780
Stage 1	677 (30.3)	22,601 (30.5)	0.945 (0.849–1.052)	0.299	0.964 (0.864–1.076)	0.516
Stage 2	279 (12.5)	8,584 (11.6)	0.971 (0.837–1.125)	0.693	0.974 (0.836–1.135)	0.737
Male						
Normal	257 (29.7)	11,626 (32.3)				
Elevated	122 (14.1)	5,378 (14.9)	1.001 (0.802–1.250)	0.992	1.045 (0.830–1.316)	0.707
Stage 1	342 (39.6)	13,718 (38.1)	1.081 (0.913–1.280)	0.366	1.138 (0.954–1.357)	0.150
Stage 2	143 (16.6)	5,314 (14.7)	1.091 (0.876–1.358)	0.436	1.133 (0.902–1.423)	0.282
Female						
Normal	689 (52.3)	20,458 (54.8)				
Elevated	184 (13.7)	4,692 (12.6)	0.947 (0.798–1.124)	0.535	0.961 (0.806–1.145)	0.655
Stage 1	335 (24.9)	8,883(23.8)	0.853 (0.740–0.982)	0.027	0.866 (0.750–1.001)	0.052
Stage 2	136 (10.1)	3,270 (8.8)	0.884 (0.720–1.085)	0.239	0.879 (0.712–1.086)	0.232
Age <50 yr						
Normal	443 (56.9)	21,358 (53.4)				
Elevated	93 (12.0)	5,134 (12.8)	0.878 (0.697–1.106)	0.268	0.877 (0.690–1.116)	0.286
Stage 1	205 (26.3)	11,045 (27.6)	0.892 (0.744–1.069)	0.215	0.929 (0.770–1.120)	0.442
Stage 2	37 (4.8)	2,481 (6.2)	0.662 (0.462–0.949)	0.025	0.721 (0.496–1.048)	0.087
Age 50–69 yr						
Normal	450 (38.4)	8,417 (36.6)				
Elevated	171 (14.6)	3,225 (14.0)	1.021 (0.848–1.229)	0.826	1.043 (0.863–1.260)	0.666
Stage 1	378 (32.2)	8,036 (35.0)	0.951(0.822–1.100)	0.497	0.988 (0.851–1.147)	0.872
Stage 2	174 (14.8)	3,296 (14.3)	1.091 (0.903–1.319)	0.365	1.098 (0.904–1.334)	0.347
Age ≥70 yr						
Normal	53 (20.6)	2,309 (22.3)				
Elevated	42 (16.3)	1,711 (16.5)	1.012 (0.666–1.536)	0.957	1.034 (0.671–1.594)	0.879
Stage 1	94 (36.6)	3,520 (34.0)	1.084 (0.764–1.539)	0.651	1.010 (0.703–1.451)	0.958
Stage 2	68 (26.5)	2,807 (27.1)	1.008 (0.693–1.466)	0.967	0.934 (0.632–1.380)	0.731

(*Continued to the next page*)

Supplemental Table S5. Continued

	No. (%)		Total cohort		PS-matched cohort	
	Case	Control	Adjusted OR (95% CI)	*P* value	Adjusted OR (95% CI)	*P* value
Fasting blood sugar, mg/dL						
Overall						
Normal	1,414 (63.4)	48,240 (65.1)				
IFG	609 (27.3)	19,858 (26.8)	0.954 (0.862–1.056)	0.363	0.937 (0.844–1.041)	0.224
≥126	185 (8.3)	5,239 (7.1)	1.145 (0.966–1.357)	0.118	1.157 (0.970–1.380)	0.104
Male						
Normal	473 (54.7)	20,722 (57.5)				
IFG	304 (35.2)	11,880 (33.0)	1.006 (0.864–1.171)	0.939	0.966 (0.824–1.132)	0.667
≥126	87 (10.1)	3,434 (9.5)	0.997 (0.776–1.281)	0.980	0.989 (0.761–1.285)	0.936
Female						
Normal	941 (70.0)	27,518 (73.8)				
IFG	305 (22.7)	7,978 (21.4)	0.917 (0.799–1.052)	0.217	0.910 (0.791–1.048)	0.192
≥126	98 (7.3)	1,805 (4.8)	1.341 (1.064–1.690)	0.013	1.328 (1.046–1.687)	0.020
Age <50 yr						
Normal	597 (76.7)	30,680 (76.7)				
IFG	162 (20.8)	8,295 (20.7)	0.995 (0.828–1.195)	0.954	0.995 (0.821–1.204)	0.955
≥126	19 (2.4)	1,048 (2.6)	0.848 (0.523–1.374)	0.503	0.956 (0.576–1.585)	0.861
Age 50–69 yr						
Normal	694 (59.2)	12,779 (55.6)				
IFG	351 (29.9)	7,709 (33.6)	0.917 (0.800–1.051)	0.213	0.907 (0.789–1.042)	0.169
≥126	128 (10.9)	2,487 (10.8)	1.228 (0.996–1.515)	0.055	1.196 (0.963–1.485)	0.106
Age ≥70 yr						
Normal	123 (47.9)	4,781 (46.2)				
IFG	96 (37.4)	3,854 (37.3)	1.029 (0.780–1.359)	0.838	0.979 (0.734–1.304)	0.884
≥126	38 (14.8)	1,704 (16.6)	1.074 (0.731–1.579)	0.716	1.094 (0.731–1.637)	0.664

OR, odds ratio; COVID-19, coronavirus disease 2019; PS, propensity score; CI, confidence interval; IFG, impaired fasting glucose.